abstract in less than 20 years, the first selective type 5 phosphodiesterase inhibitor, sildenafil, has evolved from a potential anti-angina drug to an on-demand oral treatment for erectile dysfunction (viagra), and more recently to a new orally active treatment for pulmonary hypertension (revatio).